The stock of Inovio Pharmaceuticals Inc (INO) has gone down by -23.34% for the week, with a -25.10% drop in the past month and a -45.97% drop in the past quarter. The volatility ratio for the week is 5.41%, and the volatility levels for the past 30 days are 4.33% for INO. The simple moving average for the last 20 days is -21.53% for INO’s stock, with a simple moving average of -51.01% for the last 200 days.
Is It Worth Investing in Inovio Pharmaceuticals Inc (NASDAQ: INO) Right Now?
INO has 36-month beta value of 0.79. Analysts have mixed views on the stock, with 4 analysts rating it as a “buy,” 2 as “overweight,” 3 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for INO is 25.74M, and currently, short sellers hold a 13.62% ratio of that float. The average trading volume of INO on November 15, 2024 was 306.84K shares.
INO) stock’s latest price update
The stock price of Inovio Pharmaceuticals Inc (NASDAQ: INO) has dropped by -10.96 compared to previous close of 4.77. Despite this, the company has seen a fall of -23.34% in its stock price over the last five trading days. seekingalpha.com reported 2024-11-14 that Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) Q3 2024 Earnings Call Transcript November 14, 2024 4:30 PM ET Company Participants Thomas Hong – Manager of IR Jacqui Shea – President and CEO Mike Sumner – CMO Steve Egge – CCO Peter Kies – CFO Matthew Morrow – VP of Translational Sciences Conference Call Participants Jay Olson – Oppenheimer Roy Buchanan – Citizens JMP Sudan Loganathan – Stephens Liang Cheng – Jefferies Operator Good afternoon, ladies and gentlemen, and welcome to the Inovio Third Quarter 2024 Financial Results Conference Call. At this time, all lines are in a listen-only mode.
Analysts’ Opinion of INO
Many brokerage firms have already submitted their reports for INO stocks, with Stephens repeating the rating for INO by listing it as a “Overweight.” The predicted price for INO in the upcoming period, according to Stephens is $20 based on the research report published on May 14, 2024 of the current year 2024.
Oppenheimer, on the other hand, stated in their research note that they expect to see INO reach a price target of $4. The rating they have provided for INO stocks is “Outperform” according to the report published on January 25th, 2024.
INO Trading at -26.15% from the 50-Day Moving Average
After a stumble in the market that brought INO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -71.20% of loss for the given period.
Volatility was left at 4.33%, however, over the last 30 days, the volatility rate increased by 5.41%, as shares sank -25.13% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -33.12% lower at present.
During the last 5 trading sessions, INO fell by -24.19%, which changed the moving average for the period of 200-days by -20.90% in comparison to the 20-day moving average, which settled at $5.41. In addition, Inovio Pharmaceuticals Inc saw -30.60% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for INO
Current profitability levels for the company are sitting at:
- -134895.78 for the present operating margin
- -7.67 for the gross margin
The net margin for Inovio Pharmaceuticals Inc stands at -124147.37. The total capital return value is set at -0.33. Equity return is now at value -91.42, with -66.32 for asset returns.
Based on Inovio Pharmaceuticals Inc (INO), the company’s capital structure generated 0.14 points at debt to capital in total, while cash flow to debt ratio is standing at -6.78. The debt to equity ratio resting at 0.17. The interest coverage ratio of the stock is -59630.72.
Currently, EBITDA for the company is -130.39 million with net debt to EBITDA at 0.34. When we switch over and look at the enterprise to sales, we see a ratio of -44872.44. The receivables turnover for the company is 0.0for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.45.
Conclusion
To put it simply, Inovio Pharmaceuticals Inc (INO) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
